长春高新(000661) - 2015年6月4日投资者关系活动记录表

Group 1: Future Development and Management Philosophy - The company focuses on the health industry with an international perspective, investing in high-tech products and high-growth sectors [1] - Plans to establish a biopharmaceutical technology R&D platform for mergers, incubation, and nurturing cutting-edge technology projects [1] - Emphasis on industrial mergers, targeting projects and pharmaceutical companies with market advantages and growth potential [1] Group 2: Management Model and Capital Operations - The current investment holding management model will adapt to the evolving multi-level capital market and market-oriented reforms [2] - Accelerating the company's investment strategy in response to market changes [2] Group 3: Sales Channel Development - Sales channel construction has been in planning for several years, with a professional team being assembled and specific plans undergoing final verification [3] Group 4: Internet Marketing Initiatives - The company is developing an internet marketing strategy based on customer engagement, with results expected soon [4] Group 5: Impact of Media Reports - The negative impact from the "Changsha incident" is gradually diminishing, with a new marketing mechanism established to enhance market sales [5] Group 6: Performance Outlook - Despite product price reductions, the company expects its performance in 2015 to exceed the industry average growth rate [6] - Future performance is projected to show a trend of lower growth initially, followed by higher growth as new products are launched [6] Group 7: Product Approvals and Market Expansion - The approval of follicle-stimulating hormone opens opportunities in the assisted reproductive market, with plans to expand in both growth hormone and reproductive health sectors [7] - The long-acting growth hormone is being promoted according to the established market plan, with ongoing clinical trials [8] Group 8: Clinical Progress and Future Projects - The project for the raw material and water injection production facilities is completed, with products awaiting approval from regulatory authorities [10] - The company does not plan to hold shares in its subsidiaries due to regulatory restrictions [10]